Welcome to LookChem.com Sign In|Join Free
  • or
Urea, N-(2-chlorophenyl)-N'-[3-(trifluoromethyl)phenyl]-, also known as 1-(2-chlorophenyl)-3-[3-(trifluoromethyl)phenyl]urea, is an organic compound with the chemical formula C14H9ClF3N2O. It is a derivative of urea, featuring a 2-chlorophenyl group attached to one nitrogen atom and a 3-(trifluoromethyl)phenyl group attached to the other nitrogen atom. Urea, N-(2-chlorophenyl)-N'-[3-(trifluoromethyl)phenyl]- is a white crystalline solid and is used as a chemical intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure, with the presence of chlorine and trifluoromethyl groups, contributes to its reactivity and potential applications in the development of new compounds with specific properties.

91286-93-0

Post Buying Request

91286-93-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

91286-93-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 91286-93-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,1,2,8 and 6 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 91286-93:
(7*9)+(6*1)+(5*2)+(4*8)+(3*6)+(2*9)+(1*3)=150
150 % 10 = 0
So 91286-93-0 is a valid CAS Registry Number.

91286-93-0Downstream Products

91286-93-0Relevant academic research and scientific papers

A back-to-front fragment-based drug design search strategy targeting the DFG-out pocket of protein tyrosine kinases

Iwata, Hidehisa,Oki, Hideyuki,Okada, Kengo,Takagi, Terufumi,Tawada, Michiko,Miyazaki, Yasushi,Imamura, Shinichi,Hori, Akira,Lawson, J. David,Hixon, Mark S.,Kimura, Hiroyuki,Miki, Hiroshi

, p. 342 - 346 (2012)

We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 91286-93-0